Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.53
-0.8%
$12.66
$5.22
$27.38
$157.73M0.43146,136 shs93,634 shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.38
-2.7%
$0.39
$0.22
$4.79
$16.18M-0.23845,984 shs274,427 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$1.05
-1.9%
$1.22
$1.01
$42.94
$4.68M2.24213,065 shs101,418 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.73
-1.4%
$0.89
$0.72
$2.29
$28.65M1.65160,992 shs66,881 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lifevantage Corporation stock logo
LFVN
Lifevantage
-0.79%+0.80%-1.57%-18.95%+87.29%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-2.66%-7.29%+5.15%-5.24%-80.41%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-1.87%-10.26%-11.76%-25.00%-97.53%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-1.38%-9.08%-4.75%-29.40%-61.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.9597 of 5 stars
3.50.01.72.72.61.71.3
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
1.981 of 5 stars
3.14.00.00.00.60.01.3
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.1285 of 5 stars
0.03.00.00.00.00.00.6
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.1726 of 5 stars
0.02.00.00.00.60.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50143.42% Upside
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.25
Hold$4.921,193.86% Upside
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.00
N/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest LFVN, SCYX, LPTX, and MBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lifevantage Corporation stock logo
LFVN
Lifevantage
$222.35M0.71$0.88 per share14.32$2.05 per share6.11
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$0.91 per shareN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A($2.11) per shareN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$2.63M10.89N/AN/A$1.45 per share0.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.16N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$21.29M-$0.56N/A14.68N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)

Latest LFVN, SCYX, LPTX, and MBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million
5/14/2025Q1 2025
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A-$0.05N/A-$0.05N/AN/A
5/13/2025Q1 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.38-$0.37+$0.01-$0.37N/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/26/2025Q4 2024
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.39-$0.37+$0.02-$0.37N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.44%N/A26.09%3 Years
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A

Latest LFVN, SCYX, LPTX, and MBIO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
2.41
2.41
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
1.34
1.34
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
5.83
5.83

Institutional Ownership

CompanyInstitutional Ownership
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
9.95%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
7.50%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.21%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.86%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million38.33 millionOptionable
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1004.38 million4.37 millionNot Optionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6039.02 million37.12 millionOptionable

Recent News About These Companies

Scynexis to present preclinical data on SCY-247 at ESCMID Meeting
SCYNEXIS Full Year 2024 Earnings: Misses Expectations
Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.53 -0.10 (-0.79%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$12.52 0.00 (-0.04%)
As of 06/20/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.38 -0.01 (-2.66%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$0.38 +0.00 (+0.79%)
As of 06/20/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Mustang Bio stock logo

Mustang Bio NASDAQ:MBIO

$1.05 -0.02 (-1.87%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.07 +0.02 (+1.52%)
As of 06/20/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.73 -0.01 (-1.38%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$0.78 +0.05 (+6.24%)
As of 06/20/2025 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.